US20070104721A1 - Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272 - Google Patents

Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272 Download PDF

Info

Publication number
US20070104721A1
US20070104721A1 US11/592,066 US59206606A US2007104721A1 US 20070104721 A1 US20070104721 A1 US 20070104721A1 US 59206606 A US59206606 A US 59206606A US 2007104721 A1 US2007104721 A1 US 2007104721A1
Authority
US
United States
Prior art keywords
herceptin
hki
rapamycin
mammal
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/592,066
Other languages
English (en)
Inventor
Laurence Moore
Charles Zacharchuk
Sridhar Rabindran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37845244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070104721(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to US11/592,066 priority Critical patent/US20070104721A1/en
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RABINDRAN, SRIDHAR K., MOORE, LAURENCE, ZACHARCHUK, CHARLES
Publication of US20070104721A1 publication Critical patent/US20070104721A1/en
Priority to US12/539,914 priority patent/US20090297519A1/en
Priority to US13/454,768 priority patent/US20120308560A1/en
Priority to US13/874,147 priority patent/US10729672B2/en
Priority to US17/548,340 priority patent/US20220354820A1/en
Priority to US17/871,397 priority patent/US20230201155A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • FIG. 3 is a 3-dimensional contour plot with the plane at 0% representing additive interaction, and peaks and valleys representing areas of synergy or antagonism between the herceptin and HKI-272 in MDA-MB-361 [HER-2 + (non-amplified); adenocarcinoma; ATCC HTB 27] cells.
  • an HKI-272 refers to a compound having the following core, or a derivative or pharmaceutically acceptable salt thereof. Suitable derivatives may include, e.g., an ester, ether, or carbamate.
  • the core structure, HKI-272 has the chemical name (E)-N- ⁇ 4-[3-chloro-4-(2-pyridinylmethoxy) anilino]-3-cyano-7-ethoxy-6-quinolinyl ⁇ -4-(dimethylam ino)-2-butenamide.
  • a pharmaceutical pack contains a course of treatment of a neoplasm for one individual mammal, wherein the pack contains units of an mTOR inhibitor in unit dosage form and units of herceptin in unit dosage form, optionally further in combination with units of an HKI-272 in unit dosage form.
  • a pharmaceutical pack contains a course of treatment of a neoplasm for one individual mammal, wherein the pack contains units of an mTOR inhibitor in unit dosage form and units of HKI-272 in unit dosage form, optionally further in combination with units of herceptin in unit dosage form.
  • herceptin single doses and multiple doses are contemplated.
  • a single loading dose of herceptin is administered as a 90-minute intravenous infusion in a range of about 4-5 mg/kg on day 1, followed by about 2 mg/kg per week starting on day 8.
  • 3 weeks is 1 cycle. From 1, to 2 to 3, weeks may be provided between cycles.
  • Herceptin may also be given at a dose of 6 mg/kg once every 3-4 weeks.
  • herceptin may also be given after completion of chemotherapy as maintenance therapy.
  • a compound of the invention is in the form of a unit dose.
  • Suitable unit dose forms include tablets, capsules and powders in sachets or vials.
  • Such unit dose forms may contain from 0.1 to 300 mg of a compound of the invention and preferably from 2 to 100 mg.
  • Still further preferred unit dosage forms contain 5 to 50 mg of a compound of the present invention.
  • the compounds of the present invention can be administered at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg.
  • the compounds are administered orally from 1 to 6 times a day, more usually from I to 4 times a day.
  • the compounds may be administered through another suitable route, e.g., intravenous.
  • Fludarabine (9-H-Purin-6-amine,2-fluoro-9-(5-O-phosphono-(beta)-D-a-rabinofuranosyl) is commercially available as a liquid injectable containing 50 mg/vial (FLUDARA).
  • 6-Mercaptopurine (1,7-dihydro-6H-purine-6-thione) is commercially available in 50 mg oral tablets (PURINETHOL).
  • the invention includes a product or pharmaceutical pack containing a course of an anti-neoplastic treatment for one individual mammal comprising one or more container(s) having one, one to four, or more unit(s) of an mTOR inhibitor (e.g., temsirolimus) in unit dosage form and, optionally, one, one to four, or more unit(s) of herceptin, and optionally, another active agent.
  • an mTOR inhibitor e.g., temsirolimus
  • Temsirolimus is administered IV weekly over a 30-minute period using an in-line filter and an automatic dispensing pump.
  • antihistamine diphenhydramine, 25 to 50 mg IV or the equivalent
  • temsirolimus infusion is administered.
  • the Pritchard and Shipman method was modified to allow determination of the combination effects at different levels of statistical significance (p-values 0.05, 0.01, 0.001). A p-value of 0.05 is considered significant.
  • the method of estimating statistical variability within each experiment was also modified. Variability was determined across all compound combinations, whereas in the original version, variability was estimated separately for each compound combination. It is believed that better estimates of the variability are obtained with the modified approach. In general, single points of synergy or antagonism are not considered representative of either synergistic or antagonistic activity. Thus, single point peaks or valleys are disregarded in the analysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
US11/592,066 2005-11-04 2006-11-02 Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272 Abandoned US20070104721A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US11/592,066 US20070104721A1 (en) 2005-11-04 2006-11-02 Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
US12/539,914 US20090297519A1 (en) 2005-11-04 2009-08-12 ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272
US13/454,768 US20120308560A1 (en) 2005-11-04 2012-04-24 Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272
US13/874,147 US10729672B2 (en) 2005-11-04 2013-04-30 Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
US17/548,340 US20220354820A1 (en) 2005-11-04 2021-12-10 Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
US17/871,397 US20230201155A1 (en) 2005-11-04 2022-07-22 Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73356205P 2005-11-04 2005-11-04
US83750906P 2006-08-14 2006-08-14
US11/592,066 US20070104721A1 (en) 2005-11-04 2006-11-02 Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/539,914 Division US20090297519A1 (en) 2005-11-04 2009-08-12 ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272

Publications (1)

Publication Number Publication Date
US20070104721A1 true US20070104721A1 (en) 2007-05-10

Family

ID=37845244

Family Applications (6)

Application Number Title Priority Date Filing Date
US11/592,066 Abandoned US20070104721A1 (en) 2005-11-04 2006-11-02 Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
US12/539,914 Abandoned US20090297519A1 (en) 2005-11-04 2009-08-12 ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272
US13/454,768 Abandoned US20120308560A1 (en) 2005-11-04 2012-04-24 Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272
US13/874,147 Active 2027-02-14 US10729672B2 (en) 2005-11-04 2013-04-30 Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
US17/548,340 Pending US20220354820A1 (en) 2005-11-04 2021-12-10 Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
US17/871,397 Pending US20230201155A1 (en) 2005-11-04 2022-07-22 Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12/539,914 Abandoned US20090297519A1 (en) 2005-11-04 2009-08-12 ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272
US13/454,768 Abandoned US20120308560A1 (en) 2005-11-04 2012-04-24 Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272
US13/874,147 Active 2027-02-14 US10729672B2 (en) 2005-11-04 2013-04-30 Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
US17/548,340 Pending US20220354820A1 (en) 2005-11-04 2021-12-10 Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
US17/871,397 Pending US20230201155A1 (en) 2005-11-04 2022-07-22 Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272

Country Status (17)

Country Link
US (6) US20070104721A1 (es)
EP (2) EP1942937A1 (es)
JP (7) JP2009514870A (es)
KR (1) KR101354828B1 (es)
CN (1) CN103110948A (es)
AR (1) AR057854A1 (es)
AU (1) AU2006311877A1 (es)
BR (1) BRPI0618042A2 (es)
CA (1) CA2626326C (es)
CR (1) CR9901A (es)
EC (1) ECSP088423A (es)
IL (1) IL190805A (es)
NO (1) NO20081837L (es)
PE (1) PE20070763A1 (es)
RU (2) RU2451524C2 (es)
TW (1) TW200803892A (es)
WO (1) WO2007056118A1 (es)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054001A1 (en) * 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
US20090312360A1 (en) * 2008-06-17 2009-12-17 Wyeth Antineoplastic Combinations Containing HKI-272 and Vinorelbine
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US20100087482A1 (en) * 2005-02-03 2010-04-08 Haber Daniel A Method for Treating Gefitinib Resistant Cancer
US20100113474A1 (en) * 2008-08-04 2010-05-06 Wyeth Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine
US20100260733A1 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti aging agents and methods to identify them
WO2010117633A1 (en) 2009-04-06 2010-10-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US20110111059A1 (en) * 2008-05-21 2011-05-12 Jianhui Guo Compositions Comprising Quinazoline Derivatives, Preparation Methods and Uses Thereof
WO2011070499A1 (en) 2009-12-11 2011-06-16 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
US20110165257A1 (en) * 2009-11-09 2011-07-07 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2011087926A1 (en) 2010-01-13 2011-07-21 Wyeth Llc A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR
US9139558B2 (en) 2007-10-17 2015-09-22 Wyeth Llc Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2018133838A1 (zh) * 2017-01-22 2018-07-26 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
US10729672B2 (en) 2005-11-04 2020-08-04 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
EP2591775A1 (en) * 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
WO2008121467A2 (en) * 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
NZ589269A (en) * 2008-05-16 2013-03-28 Pharma Mar Sa Combination therapy with an antitumor alkaloid
WO2010070117A1 (en) * 2008-12-18 2010-06-24 Universite Libre De Bruxelles Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
NZ619375A (en) 2009-04-28 2015-03-27 Proteus Digital Health Inc Highly reliable ingestible event markers and methods for using the same
WO2011127252A2 (en) 2010-04-07 2011-10-13 Proteus Biomedical, Inc. Miniature ingestible device
EP2642983A4 (en) 2010-11-22 2014-03-12 Proteus Digital Health Inc DEVICE INGREABLE WITH PHARMACEUTICAL PRODUCT
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
WO2014144738A1 (en) 2013-03-15 2014-09-18 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
TWI482782B (zh) 2013-05-31 2015-05-01 Univ Nat Chiao Tung 架接抗體之雙乳化核殼奈米結構
WO2015017728A1 (en) 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
US20180057603A1 (en) * 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
LT3033086T (lt) * 2013-08-14 2021-12-27 Novartis Ag Kombinuota terapija vėžiui gydyti
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
TWI735689B (zh) 2016-10-26 2021-08-11 日商大塚製藥股份有限公司 製造含有可攝食性事件標記之膠囊之方法
RU2648642C1 (ru) * 2017-06-06 2018-03-26 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ неоадъювантного лечения больных местно-распространенным раком шейки матки
JP7317343B2 (ja) * 2019-03-20 2023-07-31 公立大学法人大阪 乳がんの予防又は治療剤及び乳がん細胞の増殖抑制剤
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof
GB202111193D0 (en) 2021-08-03 2021-09-15 Phoremost Ltd Pharmaceutical compounds

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6387371B1 (en) * 1988-01-12 2002-05-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US20020183240A1 (en) * 2001-04-06 2002-12-05 Wyeth Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
US6511986B2 (en) * 2000-08-11 2003-01-28 Wyeth Method of treating estrogen receptor positive carcinoma
US20030153593A1 (en) * 2000-11-15 2003-08-14 Wyeth Use of CCI-779 as an antineoplastic agent
US6617333B2 (en) * 2001-08-07 2003-09-09 Wyeth Antineoplastic combinations comprising
US20040039010A1 (en) * 2002-05-30 2004-02-26 Grupp Stephan A. Methods for treatment of acute lymphocytic leukemia
US20040176339A1 (en) * 2003-03-05 2004-09-09 Wyeth Antineoplastic combinations
US6821515B1 (en) * 1995-07-27 2004-11-23 Genentech, Inc. Protein formulation
US20040258662A1 (en) * 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
US20050032825A1 (en) * 2002-02-01 2005-02-10 Metcalf Chester A. Phosphorus-containing compounds and uses thereof
US20050059678A1 (en) * 2003-09-15 2005-03-17 Wyeth Protein tyrosine kinase enzyme inhibitors
US20050272758A1 (en) * 2004-03-11 2005-12-08 Wyeth Antineoplastic combinations of CCI-779 and rituximab
US20060035904A1 (en) * 2001-04-06 2006-02-16 Wyeth Antineoplastic combinations
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
TW254946B (es) 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
PL181304B1 (pl) 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
JP3437685B2 (ja) 1995-09-12 2003-08-18 株式会社東芝 交直変換装置の制御保護システム
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6426383B1 (en) 1997-05-28 2002-07-30 Nalco Chemical Company Preparation of water soluble polymer dispersions from vinylamide monomers
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
EP1117659B1 (en) 1998-09-29 2003-12-03 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
KR20020071931A (ko) 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
IL157898A0 (en) * 2001-04-06 2004-03-28 Wyeth Corp Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
PL392652A1 (pl) * 2001-05-16 2010-12-06 Novartis Ag Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
SG153647A1 (en) * 2001-06-01 2009-07-29 Wyeth Corp Antineoplastic combinations
US7521175B2 (en) 2001-06-14 2009-04-21 The Regents Of The University Of California Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
KR20050044599A (ko) 2001-11-27 2005-05-12 와이어쓰 홀딩스 코포레이션 Ｅｇｆ-ｒ 및 ｈｅｒ2 키나아제의 억제제로서의3-시아노퀴놀린
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2003103676A2 (en) 2002-06-05 2003-12-18 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
DK1553940T3 (da) 2002-07-30 2008-06-02 Wyeth Corp Patenterale formuleringer indeholdende en rapamycin-hydroxyester
CN100415233C (zh) 2002-09-17 2008-09-03 惠氏公司 口服制剂
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
CN1437942A (zh) 2003-02-08 2003-08-27 杭州华卫制药技术开发有限公司 注射用长春瑞滨粉针剂及制备方法
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
BRPI0413255A (pt) 2003-08-01 2006-10-03 Wyeth Corp uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
RU2339639C2 (ru) 2003-08-07 2008-11-27 Уайт Региоселективный синтез cci-779
MXPA06001590A (es) 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
AU2003304497B2 (en) 2003-09-15 2010-06-24 Wyeth Llc Substituted quinolines as protein tyrosine kinase enzyme inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
WO2005049021A1 (en) 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
CA2566823A1 (en) 2003-11-05 2005-05-19 Board Of Regents, The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
US7235564B2 (en) 2003-12-04 2007-06-26 Amr Technology, Inc. Vinorelbine derivatives
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
CN104774931B (zh) 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
WO2005118876A2 (en) 2004-06-04 2005-12-15 Genentech, Inc. Egfr mutations
MX2007000944A (es) 2004-07-23 2007-04-13 Astrazeneca Ab Metodo para pronosticar la sensibilidad de un tumor a farmacos del receptor erbb.
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
TW200626610A (en) 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
US20060084666A1 (en) 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
US20080268034A1 (en) 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
WO2006081985A1 (en) 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
SI1859793T1 (sl) 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
US8828429B2 (en) 2005-03-03 2014-09-09 Takeda Pharmaceutical Company Limited Release-control composition
WO2006098978A1 (en) 2005-03-09 2006-09-21 Abbott Laboratories Diagnostics method for identifying candidate patients for the treatment with trastuzumab
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060235006A1 (en) 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
KR20080002826A (ko) * 2005-04-14 2008-01-04 와이어쓰 게피티니브 내성 환자에서의 표피 성장 인자 수용체（ｅｇｆｒ） 키나제 억제제의 용도
US20110045459A1 (en) 2005-04-21 2011-02-24 Mischel Paul S Molecular determinants of EGFR kinase inhibitor response in glioblastoma
ATE460937T1 (de) 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
US20080193448A1 (en) 2005-05-12 2008-08-14 Pfizer Inc. Combinations and Methods of Using an Indolinone Compound
WO2006127205A2 (en) 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
BRPI0610147A2 (pt) 2005-05-25 2010-06-01 Wyeth Corp método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
DE102005053679A1 (de) 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
WO2007011619A2 (en) 2005-07-15 2007-01-25 Wyeth Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
CA2624613A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an erbb receptor drug
US20110052570A1 (en) 2005-10-26 2011-03-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
WO2007056117A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
DK1948180T3 (da) 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
CN101312737B (zh) 2005-11-24 2012-11-14 爱库里斯股份有限两合公司 副痘病毒与传统细胞毒性化疗剂联合作为治疗癌症的生化治疗
JP2007145745A (ja) 2005-11-25 2007-06-14 Osaka Univ 変異型ＥＧＦＲ下流シグナルを抑制するＳｒｃファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
CA2632213A1 (en) 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
WO2007095038A2 (en) 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
CA2644841C (en) 2006-04-07 2013-07-16 Novartis Ag Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
TW200808728A (en) 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
EP2032989B2 (en) 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Igfbp2 biomarker
ES2385613T3 (es) 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
CA2664697A1 (en) 2006-09-28 2008-04-10 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
US20090317456A1 (en) 2006-10-13 2009-12-24 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
WO2008076257A2 (en) 2006-12-13 2008-06-26 Schering Corporation Treating cancer with anti-igflr antibody 19d12 = sch 717454
NZ578329A (en) 2006-12-13 2012-05-25 Schering Corp Igf1r inhibitors for treating cancer
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
JP5406039B2 (ja) 2006-12-21 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
CN101631536A (zh) 2007-01-12 2010-01-20 惠氏公司 片中片组合物
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
ES2639854T3 (es) 2007-02-01 2017-10-30 Takeda Pharmaceutical Company Limited Preparación de comprimidos sin causar problemas de fabricación de comprimidos
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
EP1978106A1 (en) 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
CA2684265A1 (en) 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
ES2569215T3 (es) 2007-09-10 2016-05-09 Boston Biomedical, Inc. Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer
WO2009042613A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101918579A (zh) 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
JP2011502571A (ja) 2007-11-05 2011-01-27 ピュアテック ベンチャーズ 医薬化合物を投与するための方法、キット、および組成物
CN101185633A (zh) 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼拉替尼缓释植入剂
MX2010006854A (es) 2007-12-18 2010-09-09 Schering Corp Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
CA2716826C (en) 2008-02-25 2017-05-09 Prometheus Laboratories Inc. Drug selection for breast cancer therapy using antibody-based arrays
WO2009111073A2 (en) 2008-03-06 2009-09-11 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
EP2259797A2 (en) 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20110182888A1 (en) 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
NZ588710A (en) 2008-04-18 2012-12-21 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
CN104250280A (zh) 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
WO2009129545A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
KR20180128078A (ko) 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
JP5758801B2 (ja) 2008-07-22 2015-08-05 トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ 単環式シアノエノンおよびその使用方法説明
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
US20100069340A1 (en) 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
EP3075864A1 (en) 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
CN102223886A (zh) 2008-11-07 2011-10-19 安龙制药公司 Erbb-3(her3)选择性组合疗法
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
AU2010210636A1 (en) 2009-02-04 2011-09-22 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
WO2010098627A2 (ko) 2009-02-27 2010-09-02 한올바이오파마주식회사 약제학적 제제
US9073916B2 (en) 2009-03-11 2015-07-07 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
AR076053A1 (es) 2009-04-14 2011-05-18 Schering Corp Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
ES2659725T3 (es) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
CN102470109A (zh) 2009-07-02 2012-05-23 惠氏有限责任公司 3-氰基喹啉片剂制剂及其应用
KR20110007985A (ko) 2009-07-17 2011-01-25 한올바이오파마주식회사 Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
WO2011008053A2 (ko) 2009-07-17 2011-01-20 한올바이오파마주식회사 Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR101211227B1 (ko) 2009-08-25 2012-12-11 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025269A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR20110021691A (ko) 2009-08-25 2011-03-04 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
US20110055838A1 (en) 2009-08-28 2011-03-03 Moyes William A Optimized thread scheduling via hardware performance monitoring
WO2011038467A1 (en) 2009-10-01 2011-04-07 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia
CN107441058A (zh) 2009-11-09 2017-12-08 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
PT2498756T (pt) 2009-11-09 2019-11-26 Wyeth Llc Formulações de comprimidos de maleato de neratinib
EP2896632B1 (en) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
US20130012465A1 (en) 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
EP2510121A1 (en) 2009-12-11 2012-10-17 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
US8338456B2 (en) 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387371B1 (en) * 1988-01-12 2002-05-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US6399063B1 (en) * 1988-01-12 2002-06-04 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6821515B1 (en) * 1995-07-27 2004-11-23 Genentech, Inc. Protein formulation
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
US6511986B2 (en) * 2000-08-11 2003-01-28 Wyeth Method of treating estrogen receptor positive carcinoma
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US20030153593A1 (en) * 2000-11-15 2003-08-14 Wyeth Use of CCI-779 as an antineoplastic agent
US20020183240A1 (en) * 2001-04-06 2002-12-05 Wyeth Antineoplastic combinations
US20050187184A1 (en) * 2001-04-06 2005-08-25 Wyeth Antineoplastic combinations
US20060035904A1 (en) * 2001-04-06 2006-02-16 Wyeth Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
US20060030547A1 (en) * 2001-06-01 2006-02-09 Wyeth Antineoplastic combinations
US6617333B2 (en) * 2001-08-07 2003-09-09 Wyeth Antineoplastic combinations comprising
US20050032825A1 (en) * 2002-02-01 2005-02-10 Metcalf Chester A. Phosphorus-containing compounds and uses thereof
US20040039010A1 (en) * 2002-05-30 2004-02-26 Grupp Stephan A. Methods for treatment of acute lymphocytic leukemia
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20040176339A1 (en) * 2003-03-05 2004-09-09 Wyeth Antineoplastic combinations
US20040258662A1 (en) * 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
US20050059678A1 (en) * 2003-09-15 2005-03-17 Wyeth Protein tyrosine kinase enzyme inhibitors
US20050272758A1 (en) * 2004-03-11 2005-12-08 Wyeth Antineoplastic combinations of CCI-779 and rituximab

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596162B2 (en) 2005-02-03 2020-03-24 Wyeth Llc Method for treating gefitinib resistant cancer
US20100087482A1 (en) * 2005-02-03 2010-04-08 Haber Daniel A Method for Treating Gefitinib Resistant Cancer
US10603314B2 (en) 2005-02-03 2020-03-31 The General Hospital Corporation Method for treating gefitinib resistant cancer
US10729672B2 (en) 2005-11-04 2020-08-04 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US10035788B2 (en) 2007-10-17 2018-07-31 Wyeth Llc Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9139558B2 (en) 2007-10-17 2015-09-22 Wyeth Llc Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9630946B2 (en) 2007-10-17 2017-04-25 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009054001A1 (en) * 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
US20110111059A1 (en) * 2008-05-21 2011-05-12 Jianhui Guo Compositions Comprising Quinazoline Derivatives, Preparation Methods and Uses Thereof
US8507010B2 (en) * 2008-05-21 2013-08-13 Shanghai Allist Pharmaceuticals, Inc. Compositions comprising quinazoline derivatives
EP3443961A1 (en) 2008-06-17 2019-02-20 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
US10111868B2 (en) 2008-06-17 2018-10-30 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
KR101922096B1 (ko) 2008-06-17 2018-11-27 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
EP3730139A1 (en) 2008-06-17 2020-10-28 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
EP3135285A1 (en) 2008-06-17 2017-03-01 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
US9511063B2 (en) 2008-06-17 2016-12-06 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
EP2915532A1 (en) 2008-06-17 2015-09-09 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
US20090312360A1 (en) * 2008-06-17 2009-12-17 Wyeth Antineoplastic Combinations Containing HKI-272 and Vinorelbine
US9265784B2 (en) 2008-08-04 2016-02-23 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP3175853A1 (en) 2008-08-04 2017-06-07 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
EP4424375A2 (en) 2008-08-04 2024-09-04 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
US20100113474A1 (en) * 2008-08-04 2010-05-06 Wyeth Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP4218760A2 (en) 2009-04-06 2023-08-02 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
EP3000467A1 (en) 2009-04-06 2016-03-30 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
WO2010117633A1 (en) 2009-04-06 2010-10-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN105999264A (zh) * 2009-04-06 2016-10-12 惠氏有限责任公司 用于乳腺癌的利用奈拉替尼的治疗方案
US9211291B2 (en) 2009-04-06 2015-12-15 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US8492110B2 (en) 2009-04-10 2013-07-23 Haiyan Qi Anti aging agents and methods to identify them
EP2965763A1 (en) 2009-04-10 2016-01-13 Haiyan Qi Anti-aging agents
US9360471B2 (en) 2009-04-10 2016-06-07 Haiyan Qi Anti-aging agents and methods to identify them
US20100260733A1 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti aging agents and methods to identify them
US8524281B2 (en) * 2009-11-09 2013-09-03 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
US20140004203A1 (en) * 2009-11-09 2014-01-02 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
US9211264B2 (en) * 2009-11-09 2015-12-15 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
US20110165257A1 (en) * 2009-11-09 2011-07-07 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
US20160222467A1 (en) * 2009-12-11 2016-08-04 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
WO2011070499A1 (en) 2009-12-11 2011-06-16 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
EP3575413A1 (en) 2009-12-11 2019-12-04 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
WO2011087926A1 (en) 2010-01-13 2011-07-21 Wyeth Llc A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR
US8338456B2 (en) 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
CN108778275A (zh) * 2017-01-22 2018-11-09 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
WO2018133838A1 (zh) * 2017-01-22 2018-07-26 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途

Also Published As

Publication number Publication date
JP2016041767A (ja) 2016-03-31
CA2626326C (en) 2021-02-16
TW200803892A (en) 2008-01-16
RU2451524C2 (ru) 2012-05-27
CR9901A (es) 2008-07-29
US20090297519A1 (en) 2009-12-03
EP1942937A1 (en) 2008-07-16
WO2007056118A1 (en) 2007-05-18
JP6040303B2 (ja) 2016-12-07
JP2009514870A (ja) 2009-04-09
US20220354820A1 (en) 2022-11-10
KR20080064156A (ko) 2008-07-08
JP6232463B2 (ja) 2017-11-15
JP6522056B2 (ja) 2019-05-29
JP2017171693A (ja) 2017-09-28
AU2006311877A1 (en) 2007-05-18
AR057854A1 (es) 2007-12-19
US10729672B2 (en) 2020-08-04
RU2008115454A (ru) 2009-12-10
US20140050721A1 (en) 2014-02-20
JP2014098040A (ja) 2014-05-29
JP5952679B2 (ja) 2016-07-13
IL190805A0 (en) 2008-11-03
NO20081837L (no) 2008-07-30
RU2632104C2 (ru) 2017-10-02
CA2626326A1 (en) 2007-05-18
US20120308560A1 (en) 2012-12-06
PE20070763A1 (es) 2007-08-08
CN103110948A (zh) 2013-05-22
BRPI0618042A2 (pt) 2011-08-16
EP3488866A1 (en) 2019-05-29
JP2012214521A (ja) 2012-11-08
JP2018203783A (ja) 2018-12-27
JP2016128524A (ja) 2016-07-14
ECSP088423A (es) 2008-06-30
RU2012100913A (ru) 2013-07-20
KR101354828B1 (ko) 2014-02-18
US20230201155A1 (en) 2023-06-29
IL190805A (en) 2011-08-31

Similar Documents

Publication Publication Date Title
US20220354820A1 (en) Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
US20070105887A1 (en) Antineoplastic combinations of temsirolimus and sunitinib malate
US20030008923A1 (en) Antineoplastic combinations
DK2656844T3 (en) ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
AU2018217257B2 (en) Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
CN101300029A (zh) mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
AU2013204788B2 (en) Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272

Legal Events

Date Code Title Description
AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOORE, LAURENCE;ZACHARCHUK, CHARLES;RABINDRAN, SRIDHAR K.;REEL/FRAME:018507/0447;SIGNING DATES FROM 20061018 TO 20061020

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION